Skip to main content
Clinical Trials/NL-OMON45269
NL-OMON45269RecruitingNot Applicable

ex vivo Repair Capacity (RECAP) in advanced breast cancer patients<br>(extension of the HRD pilot study) <br> - Repair Capacity (RECAP)

niversitair Medisch Centrum0 sites44 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
44

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 64 (—)

Inclusion Criteria

  • Breast cancer patients with local recurrent or distant metastases
  • The site of the tumor should be easy amendable for biopsy. NB: lung metastases (high risk of hematothorax) and bone metastases (not suitable for ex vivo HRD test because calcifications interfere with experimental procedures) are excluded.
  • Age >18 years
  • WHO performance status 0 or 1
  • Bilirubin <1.5 ULN and both AST and ALT <5x ULN in case a liver biopsy is planned
  • Platelets >100 x 10e9/L and INR <1.5, unless platelet/INR values are not necessary according to local protocols or after consent of the intervention radiologist for that particular site of biopsy (e.g. biopsy of the skin). Written informed consent

Exclusion Criteria

  • Current therapeutically use of anti-coagulant (coumarin derivates, warfarin, heparin or low molecular weight heparin [LMWH]) whereby a short interruption of drug use is not allowed. LMWH if used for prophylaxis is allowed. Use of low molecular weight heparin (LMWH) should be interrupted shortly before biopsy is scheduled, unless this is not necessary according to local protocols or after consent of the intervention radiologist.
  • Any psychological condition potentially hampering compliance with the study protocol

Investigators

Sponsor
niversitair Medisch Centrum

Similar Trials